Verrica Pharmaceuticals Inc. (VRCA) – What Are Investment Firms Saying About This Stock?

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) has earned an average recommendation of “Hold” from the five research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $12.67.

VRCA has been the topic of a number of research reports. Wall Street Zen cut Verrica Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday. Lake Street Capital began coverage on shares of Verrica Pharmaceuticals in a research note on Thursday, August 27th. They set a “buy” rating and a $9.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a report on Tuesday, October 13th.

Verrica Pharmaceuticals Trading Up 12.5%

Shares of VRCA opened at $3.59 on Tuesday. The stock’s 50-day moving average price is $4.20 and its 200 day moving average price is $5.49. The company has a quick ratio of 1.33, a current ratio of 1.45 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $61.68 million, a price-to-earnings ratio of -2.15 and a beta of 1.69. Verrica Pharmaceuticals has a 12-month low of $3.08 and a 12-month high of $9.82.

Institutional Trading of Verrica Pharmaceuticals

A hedge fund recently raised its position in Verrica Pharmaceuticals stock. Fifth Third Bancorp increased its holdings in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 100.0% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,000 shares of the company’s stock after purchasing an additional 14,000 shares during the period. Fifth Third Bancorp owned approximately 0.16% of Verrica Pharmaceuticals worth $134,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 42.45% of the company’s stock.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a dermatology-focused biopharmaceutical company developing and commercializing therapies for skin diseases that have limited or inadequate treatment options. The company’s activities center on prescription products designed for use by dermatologists and other healthcare professionals.

Verrica’s lead commercial product is YCANTHE (cantharidin) topical solution, 0.7%, a prescription treatment approved by the U.S. Food and Drug Administration for molluscum contagiosum in adults and children two years of age and older.